Atterocor is a biopharmaceutical company focused on treatments for two specific adrenal disorders with significant unmet medical needs.
Atterocor, Inc. is focused on developing therapies for two distinct adrenal diseases, adrenocortical carcinoma and Cushing’s syndrome. The company’s lead compound, PDX, is in late preclinical development and will enter clinical testing in early 2013. Both diseases are serious medical conditions targeting small patient populations with very limited treatment options. This provides the opportunity for an accelerated development pathway for PDX.